{"contentid": 488651, "importid": NaN, "name": "Dupixent on a roll with more positive data", "introduction": "Sanofi has presented detailed results from the Phase III VOYAGE trial, showing that Dupixent (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years.", "content": "<p>Sanofi (Euronext: SAN) has presented detailed results from the Phase III VOYAGE trial, showing that Dupixent (dupilumab) significantly reduced severe asthma attacks, and within two weeks rapidly improved lung function in children aged 6 to 11 years.</p>\n<p>Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways.</p>\n<p>The trial has been testing the impact of the therapy in children with uncontrolled moderate-to-severe asthma, with evidence of type 2 inflammation.</p>\n<p>Sanofi has placed a strong emphasis on developing Dupixent to bolster the firm&rsquo;s revenues, with an ambitious target of up to $12 billion in annual sales.</p>\n<p>The monoclonal antibody generated nearly a billion euros ($1.2 billion) in sales in the final quarter of 2020 alone, yielding full-year revenues of 3.5 billion euros.</p>\n<h2>Conference data</h2>\n<p>The results, presented at the 2021 American Thoracic Society International Conference (ATS 2021), showed Dupixent also significantly improved overall asthma symptom control.</p>\n<p>Leonard Bacharier, director at the Center for Pediatric Asthma Research, said: &ldquo;The trial results show that dupilumab, when added to standard of care therapy, significantly reduced asthma attacks, rapidly improved lung function and improved asthma control, which is especially important to these children during a particularly formative time in their lives.&rdquo;</p>\n<p>Top line results from the trial, which met its primary and key secondary endpoint, were announced in October 2020.</p>", "date": "2021-05-17 17:03:00", "meta_title": NaN, "meta_keywords": "Dupixent, asthma, trial, results, billion, improved, children, significantly, Sanofi, presented, lung, dupilumab, reduced, attacks, function, rapidly, roll", "meta_description": "Sanofi has presented detailed results from the Phase III VOYAGE trial, showing that Dupixent (dupilumab) significantly reduced severe asthma attacks, and within", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-17 17:03:07", "updated": "2021-05-17 17:08:50", "access": NaN, "url": "https://www.thepharmaletter.com/article/dupixent-on-a-roll-with-more-positive-data", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "2020_sanofi_big.jpg", "image2id": "2020_sanofi_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Dermatologicals", "topic_tag": "ATS, Conferences, Drug Trial, Research", "geography_tag": "France", "company_tag": "Sanofi", "drug_tag": "Dupixent", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-17 17:03:00"}